浙江海昇药业股份有限公司 证券代码：870656 证券简称：海昇药业 公告编号：2025-026 2024 年度独立董事述职报告（舒霖） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 本人舒霖，在浙江海昇药业股份有限公司（以下简称"公司"）2024 年度任职 期间，严格按照《公司法》《证券法》《上市公司独立董事管理办法》《北京证券 交易所股票上市规则（试行）》等法律法规和《公司章程》的规定，认真履行职责， 充分发挥独立董事的作用，恪尽职守，勤勉尽责，维护公司利益，维护全体股东尤 其是中小股东的利益，履行了独立董事的职责，谨慎、认真、勤勉地行使法律所赋 予的权利，积极出席相关会议，对各项议案进行认真审议，对公司重大事项发表了 独立意见，充分发挥了独立董事的作用。 现就本人 2024 年度的履职情况报告如下： 一、独立董事的基本情况 舒霖先生，男，1968 年 11 月出生，中国国籍，无境外永久居留权，生命科学 学院生态学专业，博士研究生学历。1992 年-2000 年任浙江省衢州第二中学教师， 2001 ...

根据《北京证券交易所股票上市规则（试行）》中相关规定，交易的成交金 额占上市公司最近一期经审计净资产的 10%以上且超过 1,000.00 万元的应当予 以披露；上市公司连续 12 个月滚动发生理财的，以该期间最高余额为成交额， 适用上述标准。 本次购买的理财产品金额为 21,210 万元，截至目前，募集资金购买的理财 产品未到期余额为 28,210 万元。 证券代码：870656 证券简称：海昇药业 公告编号：2025-020 浙江海昇药业股份有限公司 关于使用部分闲置募集资金购买理财产品的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 授权委托理财情况 （一）已授权委托理财基本信息 浙江海昇药业股份有限公司（以下简称"公司"）于 2024 年 5 月 16 日召开 第三届董事会第十六次会议、第三届监事会第十五次会议，于 2024 年 6 月 3 日召开 2024 年第二次临时股东大会，审议通过了《关于使用部分闲置募集资金 进行现金管理的议案》，在确保资金安全、不影响募集资金投资项目建 ...

浙江海昇药业股份有限公司 关于使用闲置自有资金购买理财产品的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 授权委托理财情况 证券代码：870656 证券简称：海昇药业 公告编号：2025-021 （一）已授权委托理财基本信息 公司于 2024 年 5 月 16 日召开第三届董事会第十六次会议、第三届监事会 第十五次会议，于 2024 年 6 月 3 日召开 2024 年第二次临时股东大会，审议通 过了《关于使用闲置自有资金进行现金管理的议案》，基于公司经营稳定，财务 状况稳健，有较充裕的资金及有效的风险控制制度，在确保公司正常经营活动 资金需求的前提下，公司拟使用部分闲置自有资金进行管理，以提高资金使用 效率和收益，为公司股东谋取更好的回报。公司拟进行的现金管理的金额不超 过人民币 1 亿元（含本数），资金来源为公司闲置自有资金。在上述额度内，资 金可以循环滚动使用，委托理财取得的收益可进行再投资，再投资的金额不包 含在上述额度以内。具体内容详见公司在北京证券交易所信息披露平台 （ww ...

Core Viewpoint - Haisheng Pharmaceutical (870656) experienced a significant increase of 14.89% in its stock price, with a trading volume turnover rate of 27.65% and a total transaction amount of 114 million yuan on the day of reporting [1] Trading Activity Summary - The stock was listed on the North Exchange due to its daily turnover rate reaching 27.65%, with a total net selling amount of 4.6294 million yuan from brokerage seats [1] - The top five brokerage seats accounted for a total transaction amount of 36.5448 million yuan, with buying transactions amounting to 15.9577 million yuan and selling transactions amounting to 20.5871 million yuan, resulting in a net selling amount of 4.6294 million yuan [1] Brokerage Seat Details - The largest buying brokerage seat was Guojin Securities Co., Ltd. Shenzhen Bay No. 1 Securities Brokerage Seat, with a buying amount of 3.9721 million yuan, while the largest selling brokerage seat was Huatai Securities Co., Ltd. Shanghai Wuding Road Securities Brokerage Seat, with a selling amount of 6.4812 million yuan [1] - Detailed trading activities of the top five buying and selling brokerage seats are as follows: - Buying: - Guojin Securities: 3.9721 million yuan - China International Capital Corporation Guangzhou Branch: 3.3924 million yuan - Shanghai Securities Co., Ltd. Ningbo Beilun New Dalu Securities Brokerage Seat: 2.6948 million yuan - Guosen Securities Co., Ltd. Beijing Branch: 2.4891 million yuan - Guosen Securities Co., Ltd. Shenzhen Hongling Middle Road Securities Brokerage Seat: 2.0562 million yuan - Selling: - Huatai Securities: 6.4812 million yuan - Guosen Securities Co., Ltd. Shenzhen Internet Branch: 3.7548 million yuan - Kaiyuan Securities Co., Ltd. Chengdu Branch: 3.5239 million yuan - Shenwan Hongyuan Securities Co., Ltd. Jiangsu Yancheng Century Avenue Brokerage Seat: 2.3970 million yuan - China Galaxy Securities Co., Ltd. Beijing Zhongguancun Street Securities Brokerage Seat: 2.3519 million yuan [1]

Market Overview - On March 27, the Shanghai Composite Index rose by 0.15%, with the total margin financing balance in the market at 1,926.55 billion yuan, a decrease of 3.164 billion yuan from the previous trading day [1] - The margin financing balance in the Shanghai Stock Exchange was 976.08 billion yuan, down by 1.008 billion yuan; in the Shenzhen Stock Exchange, it was 944.93 billion yuan, down by 2.182 billion yuan; and in the Beijing Stock Exchange, it was 5.543 billion yuan, up by 0.027 billion yuan [1] Industry Analysis - Among the industries classified by Shenwan, 12 industries saw an increase in financing balance, with the public utilities sector leading with an increase of 0.305 billion yuan, followed by household appliances and coal industries with increases of 0.194 billion yuan and 0.117 billion yuan, respectively [1] Individual Stock Performance - A total of 1,580 stocks experienced an increase in financing balance, accounting for 42.97% of the total, with 206 stocks showing an increase of over 5% [1] - The stock with the largest increase in financing balance was Deer Chemical, with a latest financing balance of 22.4955 million yuan, reflecting a 99.74% increase from the previous trading day, and its stock price rose by 3.06% [1] - Other notable stocks with significant increases in financing balance included Haisheng Pharmaceutical and Duorui Pharmaceutical, with increases of 75.11% and 70.60%, respectively [1] Top Gainers and Losers - Among the top 20 stocks with the largest increase in financing balance, the average increase in stock price was 2.22%, with notable gainers including Sanwei Co., Chip Microelectronics, and Haisheng Pharmaceutical, which rose by 29.96%, 12.29%, and 9.67%, respectively [2] - Conversely, the top losers included Qiuguan Cable, Baofeng Energy, and Renxin New Materials, which fell by 10.10%, 9.99%, and 4.78%, respectively [2] Margin Financing Decrease - There were 2,097 stocks that saw a decrease in financing balance, with 225 stocks experiencing a decline of over 5% [4] - The stock with the largest decrease in financing balance was Tiangang Co., with a latest financing balance of 4.0218 million yuan, down by 39.81% from the previous trading day [5] - Other stocks with significant decreases included Dayu Biological and Zhonggu Logistics, with declines of 36.89% and 35.13%, respectively [5]

Investment Rating - The investment rating for the company is "Hold (First Coverage)" [1] Core Views - The company is a national high-tech enterprise specializing in the research, production, and sales of veterinary raw materials, pharmaceutical raw materials, and intermediates, with a comprehensive product range covering various fields such as anti-infection and analgesics [6][9] - Despite a decline in revenue and net profit due to intensified market competition and reduced end demand, the company is expected to reverse its current difficulties through overseas market expansion and new product development in the pet medicine sector [6][24] - The global pharmaceutical market is projected to reach $1.9 trillion by 2027, driven by an aging population and increasing chronic disease prevalence, providing a favorable environment for the company's growth [6][24] Financial Forecast - Total revenue is forecasted to decline from 166.62 million in 2024 to 238.31 million in 2026, with growth rates of -22.54%, 14.01%, and 25.45% respectively [5] - Net profit is expected to decrease from 50.75 million in 2024 to 88.56 million in 2026, with growth rates of -40.12%, 22.39%, and 42.58% respectively [5] - The company's P/E ratios for 2024, 2025, and 2026 are projected to be 32.47, 26.53, and 18.61 respectively, indicating a potential for valuation improvement [5] Company Overview - The company was established in 2007 and went public on the Beijing Stock Exchange in February 2024, becoming one of the longest and most comprehensive suppliers of sulfonamide raw materials and intermediates in the industry [6][9][10] - The actual controllers of the company are Ye Shan Hai and Ye Jin Zhi, who collectively hold 50.5% of the shares, indicating a stable and concentrated ownership structure [6][19] Product and Business Layout - The company has a comprehensive product chain and focuses on three main areas: veterinary raw materials, pharmaceutical raw materials, and intermediates, forming a dual-driven development model of "sulfonamide + non-sulfonamide" [24][25] - Key products include sulfanilamide sodium, crystalline sulfanilamide, and celecoxib, with international certifications such as EU CEP and Japan MF [6][32] - The company is actively expanding into the pet medicine market and developing high-end intermediates, which are expected to enhance its competitive position [6][24][25] Customer Resources - The company has established stable relationships with major domestic and international clients, including ELANCO and CHORI, with overseas revenue accounting for 32.73% as of the first half of 2024 [6][35] - The top five customers contributed 51.57% of the company's revenue in the first half of 2024, indicating a relatively concentrated customer base [6][39] R&D and Innovation - The company has increased its R&D investment, with expenses growing from 6.02 million in 2019 to 9.03 million in 2023, reflecting a compound annual growth rate of 10.70% [6][41] - A new R&D center was established in May 2024, equipped with advanced facilities and talented personnel, further enhancing the company's innovation capabilities [6][41]

Investment Rating - The investment rating for the company is "Hold (First Coverage)" [1] Core Views - The company is a national high-tech enterprise specializing in the research, production, and sales of veterinary raw materials, pharmaceutical raw materials, and intermediates, with a comprehensive product range covering anti-infection and analgesic fields [6][9] - The company has a dual-driven model of "sulfonamide + non-sulfonamide" and is actively expanding into the pet medicine market and high-end intermediates [6][24] - Despite a decline in revenue and profit due to intensified market competition and reduced end demand, the company is expected to reverse its difficulties through overseas market expansion and new product development [6][24] Financial Forecast - Total revenue (in million) for 2022A, 2023A, 2024E, 2025E, and 2026E is projected to be 264.42, 215.10, 166.62, 189.96, and 238.31 respectively, with growth rates of -1.72%, -18.65%, -22.54%, 14.01%, and 25.45% [5] - Net profit attributable to the parent (in million) for the same years is forecasted to be 112.68, 84.76, 50.75, 62.11, and 88.56, with growth rates of -3.37%, -24.78%, -40.12%, 22.39%, and 42.58% [5] - The company’s P/E ratios for 2024-2026 are projected to be 32.47, 26.53, and 18.61 respectively [5] Company Overview - The company was established in 2007 and listed on the Beijing Stock Exchange in February 2024, becoming one of the most competitive enterprises in the sulfonamide raw material and intermediate industry [9][10] - The actual controllers of the company are Ye Shan Hai and Ye Jin Zhi, holding a combined 50.5% of the shares, indicating a concentrated and stable ownership structure [19] Product and Business Layout - The company focuses on three main areas: veterinary raw materials, pharmaceutical raw materials, and intermediates, with a comprehensive product chain and strong competitive position [24][25] - Key products include sulfanilamide sodium, crystalline sulfanilamide, and celecoxib, with international certifications such as EU CEP and Japan MF [6][32] Industry Analysis - The global pharmaceutical market is expected to reach $1.9 trillion by 2027, driven by an aging population and increasing chronic disease prevalence [6] - The veterinary raw material market is projected to reach $83.764 billion by 2030, with a compound annual growth rate (CAGR) of 8.2% [6]

证券代码：870656 证券简称：海昇药业 公告编号：2025-019 浙江海昇药业股份有限公司 关于使用闲置自有资金购买理财产品的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 授权委托理财情况 （一）已授权委托理财基本信息 公司于 2024 年 5 月 16 日召开第三届董事会第十六次会议、第三届监事会 第十五次会议，于 2024 年 6 月 3 日召开 2024 年第二次临时股东大会，审议通 过了《关于使用闲置自有资金进行现金管理的议案》，基于公司经营稳定，财务 状况稳健，有较充裕的资金及有效的风险控制制度，在确保公司正常经营活动 资金需求的前提下，公司拟使用部分闲置自有资金进行管理，以提高资金使用 效率和收益，为公司股东谋取更好的回报。公司拟进行的现金管理的金额不超 过人民币 1 亿元（含本数），资金来源为公司闲置自有资金。在上述额度内，资 金可以循环滚动使用，委托理财取得的收益可进行再投资，再投资的金额不包 含在上述额度以内。具体内容详见公司在北京证券交易所信息披露平台 （ww ...

证券代码：870656 证券简称：海昇药业 公告编号：2025-018 浙江海昇药业股份有限公司 关于使用部分闲置募集资金购买理财产品的进展公告 （二） 使用闲置募集资金投资理财产品的说明 公司本次使用部分闲置募集资金购买的理财产品为结构性存款，收益类型为 保本保最低收益型，市场风险小，出现本金损失的概率较低，能够满足安全性高、 流动性好、保证本金安全的要求。 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 授权委托理财情况 （一）已授权委托理财基本信息 浙江海昇药业股份有限公司（以下简称"公司"）于 2024 年 5 月 16 日召开 第三届董事会第十六次会议、第三届监事会第十五次会议，于 2024 年 6 月 3 日召开 2024 年第二次临时股东大会，审议通过了《关于使用部分闲置募集资金 进行现金管理的议案》，在确保资金安全、不影响募集资金投资项目建设的前提 下，公司拟使用额度不超过人民币 3 亿元（含本数）的闲置募集资金进行现金 管理，在上述额度范围内资金可以循环滚动使用，并授权公司董事长 ...

Financial Performance - The company's operating revenue for the reporting period is expected to be CNY 166.21 million, a decrease of 22.73% year-on-year[5]. - The net profit attributable to shareholders is expected to be CNY 50.75 million, down 40.12% compared to the previous year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be CNY 43.53 million, a decrease of 48.10% year-on-year[5]. - The basic earnings per share is expected to be CNY 0.65, a decline of 53.90% compared to the same period last year[5]. Assets and Equity - Total assets at the end of the reporting period are expected to be CNY 703.22 million, an increase of 128.78% year-on-year[5]. - The equity attributable to shareholders is expected to be CNY 652.64 million, up 129.49% from the beginning of the period[5]. Market Conditions - The company's earnings decline is primarily due to intensified market competition and reduced demand from end customers for key products[5]. - The sales price of the main veterinary raw material, Sulfamethazine Sodium, has decreased due to increased market competition[5]. - The company plans to address the decline in sales volume of Crystalline Sulfamethazine and Dexamethasone products[5]. Financial Reporting - The financial data presented is preliminary and has not been audited, indicating potential discrepancies with the final report[6].